Renaissance Technologies - ADAPTIMMUNE THERAPEUTICS PLC ownership

ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 81 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q2 2020. The put-call ratio across all filers is 1.08 and the average weighting 0.3%.

Quarter-by-quarter ownership
Renaissance Technologies ownership history of ADAPTIMMUNE THERAPEUTICS PLC
ValueSharesWeighting
Q3 2023$802
-42.4%
1,027,860
-31.8%
0.00%
-50.0%
Q2 2023$1,393
+600.0%
1,506,375
+724.5%
0.00%
Q1 2023$199
-75.7%
182,700
-67.4%
0.00%
-100.0%
Q4 2022$819
-99.9%
560,973
-0.9%
0.00%0.0%
Q3 2022$609,000
-29.8%
566,232
+11.0%
0.00%0.0%
Q2 2022$867,000
-56.1%
510,000
-46.9%
0.00%
-50.0%
Q1 2022$1,977,000
+23.3%
959,703
+124.4%
0.00%0.0%
Q4 2021$1,604,000
+24.1%
427,687
+40.9%
0.00%0.0%
Q2 2021$1,293,000
+141.2%
303,495
+200.5%
0.00%
+100.0%
Q1 2021$536,000
-88.9%
101,000
-88.7%
0.00%
-80.0%
Q4 2020$4,808,000
-54.4%
892,095
-32.5%
0.01%
-54.5%
Q3 2020$10,546,000
-38.2%
1,321,611
-22.5%
0.01%
-26.7%
Q2 2020$17,071,000
+258.6%
1,705,411
-2.5%
0.02%
+200.0%
Q1 2020$4,760,000
+170.8%
1,749,960
+19.4%
0.01%
+400.0%
Q4 2019$1,758,000
+32.5%
1,465,143
+66.7%
0.00%0.0%
Q3 2019$1,327,000
-33.6%
878,759
+76.8%
0.00%
-50.0%
Q2 2019$1,998,000
-41.5%
497,100
-37.4%
0.00%
-33.3%
Q1 2019$3,416,000
-5.1%
794,500
+26.9%
0.00%
-25.0%
Q4 2018$3,601,000
-74.3%
626,300
-39.4%
0.00%
-71.4%
Q3 2018$14,018,000
-53.5%
1,033,800
-60.4%
0.01%
-12.5%
Q2 2018$30,122,000
+105.4%
2,608,107
+99.7%
0.02%0.0%
Q1 2018$14,666,000
+120.9%
1,306,000
+31.4%
0.02%
+128.6%
Q4 2017$6,640,000
-29.8%
994,000
-13.9%
0.01%
-36.4%
Q3 2017$9,460,000
+97.0%
1,155,100
+8.0%
0.01%
+83.3%
Q2 2017$4,801,000
+11.6%
1,069,300
+36.9%
0.01%0.0%
Q1 2017$4,302,000
+138.6%
780,800
+75.4%
0.01%
+100.0%
Q4 2016$1,803,000
-22.2%
445,100
+35.4%
0.00%
-25.0%
Q3 2016$2,317,000
+50.3%
328,700
+73.7%
0.00%
+33.3%
Q2 2016$1,542,000
+67.6%
189,200
+67.1%
0.00%
+50.0%
Q1 2016$920,000
+160.6%
113,200
+286.3%
0.00%
+100.0%
Q4 2015$353,00029,3000.00%
Other shareholders
ADAPTIMMUNE THERAPEUTICS PLC shareholders Q2 2020
NameSharesValueWeighting ↓
MPM ASSET MANAGEMENT LLC 6,287,101$4,903,9392.63%
Syncona Portfolio Ltd 1,377,294$1,074,2891.60%
MPM BioImpact LLC 5,095,912$3,974,8111.06%
NEA Management Company, LLC 17,079,778$13,322,2271.03%
TANG CAPITAL MANAGEMENT LLC 5,166,954$4,030,2240.57%
PFM Health Sciences, LP 10,423,135$8,130,0450.38%
Matrix Capital Management Company, LP 38,974,185$30,399,8640.36%
Long Focus Capital Management, LLC 10,963,158$8,551,2630.31%
Acuitas Investments, LLC 479,764$374,2160.22%
Endurant Capital Management LP 311,944$243,3160.22%
View complete list of ADAPTIMMUNE THERAPEUTICS PLC shareholders